A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells.
A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells.
复制标题
DOI:
10.1158/0008-5472.can-09-4572
复制
发表时间:
2010-04-01
期刊:
影响因子:
11.2
通讯作者:
St Clair WH
中科院分区:
文献类型:
--
作者:
Sun Y;St Clair DK;Xu Y;Crooks PA;St Clair WH
Cancer cells are usually under higher oxidative stress than normal cells are. We hypothesize that introducing additional ROS insults or suppressing antioxidant capacity may selectively enhance cancer cell killing by oxidative-stress generating agents through stress overload or stress sensitization, while normal cells may be able to maintain redox homeostasis under exogenous ROS by adaptive response. Here, we demonstrate that parthenolide (PN), a sesquiterpene lactone, selectively exhibits a radiosensitization effect on prostate cancer PC3 cells but not on normal prostate epithelial PrEC cells. PN causes oxidative stress in PC3 cells but not in PrEC cells, as determined by the oxidation of the ROS-sensitive probe H2DCFDA and intracellular reduced thiol and disulfide levels. In PC3 but not PrEC cells, PN activates NADPH oxidase leading to a decrease in the level of reduced thioredoxin, activation of PI3K/Akt and consequent FOXO3a phosphorylation, which results in the downregulation of FOXO3a targets, antioxidant enzyme manganese superoxide dismutase (MnSOD) and catalase. Importantly, when combined with radiation, PN further increases ROS levels in PC3 cells, while it decreases radiation-induced oxidative stress in PrEC cells, possibly by increasing GSH level. Together, the results demonstrate that PN selectively activates NADPH oxidase and mediates intense oxidative stress in prostate cancer cells by both increasing ROS generation and decreasing antioxidant defense capacity. The results support the concept of exploiting the intrinsic differences in the redox status of cancer cells and normal cells as targets for selective cancer killing.